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background: No previous research has examined the association between metabolic syndrome (MetSyn) and
health-related quality of life (HRQoL) using standard criteria for defining MetSyn. We hypothesized that MetSyn would
be associated with lower HRQoL on measures of physical and mental health.
Methods and Procedures: Participants were 361 individuals in two randomized weight loss trials. MetSyn was
defined by the National Cholesterol Education Panel criteria. The Medical Outcomes Study, Short Form-36 (SF-36)
was used to assess HRQoL. Differences in HRQoL and in clinical and psychosocial characteristics were compared
among participants with and without MetSyn. Multiple regression was used to determine predictors of HRQoL.
Results: MetSyn was associated with lower scores on the physical function and general health subscales of the
SF-36 and on the physical component summary (PCS) score. This association remained after controlling for age or
depression but was eliminated by controlling for BMI. MetSyn was not associated with lower mental quality of life, a
higher depression score, tobacco or alcohol use, or a higher rate of psychosocial stressors.
Discussion: Individuals with MetSyn reported lower HRQoL. This appeared to be an effect of increased weight, rather
than a unique effect of MetSyn. Larger studies are needed to assess whether MetSyn may have an independent
effect on HRQoL.

IntroductIon

Metabolic syndrome (MetSyn) is associated with an increased
risk for developing type 2 diabetes, as well as cardiovascular
disease (1–3). Insulin resistance is thought to lie at the heart
of the syndrome, which is diagnosed when patients meet at
least three of the following five criteria: elevated waist circumference (>40 inches for men, >35 inches for women); high
triglycerides (>150 mg/dl); reduced high-density lipoprotein
cholesterol (<40 mg/dl for men, <50 mg/dl for women); high
fasting glucose (>100 mg/dl); and elevated blood pressure
(>130/85 mm Hg) (4).
Some investigators believe that metabolic syndrome is also
associated with an increased risk for psychiatric comorbidity,
stress, and impaired health-related quality of life (HRQoL)
(5–8). For example, two previous studies have reported that
individuals with metabolic syndrome had a reduced quality of
life, principally in the area of physical function (7,9). In these
two studies, however, unconventional criteria were used to
define MetSyn, as compared to the criteria developed by the
National Cholesterol Education Program (4) or by the World

Health Organization (10,11). In addition, these studies did
not examine whether differences in quality of life that were
attributed to MetSyn may, in fact, have been attributable to the
higher BMI of persons with the syndrome.
In the present study, we used the Medical Outcomes Study,
Short Form-36 (SF-36) (12,13) to determine whether individ
uals with metabolic syndrome had lower scores on the physi
cal health and mental health subscales of the instrument. The
physical health subscales include those that measure physical
function (i.e., degree of limitation in performing activities of
daily living), physical role (i.e., limitations in daily activities due to physical health), bodily pain (i.e., limitations in
daily activities due to pain), and general health (i.e., selfevaluation of overall health). The mental health subscales
include those that measure vitality (i.e., energy and fatigue),
social functioning (i.e., limitations in social activities due
to physical or emotional health), emotional role (i.e., limi
tations in usual role activities due to emotional problems),
and general mental health (i.e., psychological distress and
well-being). We also examined whether the hypothesized
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association between MetSyn and lower HRQoL could be
explained, in part, by a higher BMI or by a higher rate of psy
chosocial complications (e.g., depression, history of mental
illness, alcohol and tobacco abuse, and stress) among those
with the syndrome.
Methods And procedures
participants
Participants were 404 overweight and obese individuals who took
part in one of two randomized weight control trials that have been
reported previously (14,15). Participants in both studies were required
to have a BMI of 30–45 kg/m2 and were excluded if they had signifi
cant medical or psychiatric comorbidities, described previously (15).
These included uncontrolled hypertension (>140/90 mm Hg), types
1 or 2 diabetes, or the use of medications known to cause long-term
changes in weight. The presence of MetSyn was assessed using the
National Cholesterol Education Program criteria (4). Participants
who took medications for hypertension or hypercholesterolemia were
counted as meeting the blood pressure and triglyceride criteria for
metabolic syndrome.
outcomes measures
SF-36. The SF-36 was used to assess HRQoL. This measure includes
eight subscales, all of which are used to derive a summary measure
of physical health and a summary measure of mental health (12,13).
Higher scores, both on the eight subscales and the two summary mea
sures, indicate better functioning.

results
Metabolic syndrome

Participants with MetSyn had a significantly greater age (P =
0.002), height (P < 0.001), weight (P < 0.001), and BMI (P <
0.001) than those without the syndrome (Table 1). A higher
percentage of individuals with MetSyn were white (P = 0.02)
and male (P < 0.001). As expected, participants with MetSyn
also had significantly higher blood pressure, higher fasting
glucose and insulin, higher triglycerides, and lower high-den
sity lipoprotein cholesterol than did those without MetSyn
(P < 0.001 for all comparisons). Low-density lipoprotein
cholesterol levels did not differ significantly between the two
groups (Table 1).
Quality of life

Comparisons of HRQoL between participants with and with
out MetSyn are shown in Table 2. Individuals with MetSyn had
significantly lower scores on two of the eight subscales of the
table 1 Baseline characteristics of participants with and
without metabolic syndrome, among individuals seeking
weight reductiona
No metabolic
syndrome
(n = 226)

Metabolic
syndrome
(n = 135)

P value

Depression. Symptoms of depression were assessed using the Beck
Depression Inventory (BDI-II), the standard measure for depression in
mental health (16). Scores range from 0 to 63, with higher values indic
ative of greater symptoms of depression. Scores of 0–13 are considered
minimal (i.e., in the normal range). Participants also reported whether
they had a history of mental health problems, as assessed by the Weight
and Lifestyle Inventory (17).

Gender, number (%)
Female
Male

190 (84.1%)
36 (15.9%)

82 (60.7%)
53 (39.3%)

<0.001

Ethnicity
White
African American
Otherb

167 (73.9%)
56 (24.8%)
3 (1.3%)

113 (83.7%)
20 (14.8%)
2 (1.5%)

0.02

Lifestyle habits. Lifestyle habits, including smoking and alcohol
intake, were also assessed with the Weight and Lifestyle Inventory
(17). This questionnaire has good reliability for these items (18). The
Weight and Lifestyle Inventory was also used to identify ongoing
sources of stress, including those related to work, intimate relation
ships, and legal/financial troubles. Participants responded yes or no
to the presence of each of eight psychosocial stressors, as described
previously (17).

Age (year)

44.9 ± 10.0

48.2 ± 9.5

0.002

Education (year)

15.6 ± 2.3

15.7 ± 2.3

0.67

Weight (kg)

96.7 ± 18.4

109.0 ± 18.6

<0.001

statistical analysis
Full data concerning MetSyn and quality of life were available for 361
of the original 404 participants. Individuals who were not included in
the analysis data set did not differ in age, weight, BMI, education, or
ethnicity from the 361 persons for whom full data were available. If a
participant had missing data on one or more components of MetSyn
but met at least three criteria, the individual was designated as having
the syndrome.
Differences in weight and in other characteristics between participants
with and without MetSyn were compared using t-tests for continuous
variables and chi-square tests for categorical variables. Similar analyses
were used to compare individuals with and without MetSyn on: (i) the
eight subscales of the SF-36; (ii) symptoms of depression; (iii) lifestyle
habits; and (iv) psychosocial stressors.
Zero-order correlations were used to estimate the strength of asso
ciation between HRQoL and single variables of interest. Multivariable
regression was then used to assess the total variance in HRQoL explained
by all predictor variables. All analyses were conducted using Stata soft
ware, version 9.2 (Stata Corporation, College Station, TX). A P value
<0.05 was considered significant for all analyses.

Height (cm)

166.6 ± 7.7

170.4 ± 10.1

<0.001

BMI (kg/m2)

34.7 ± 5.6

37.4 ± 4.2

<0.001

Waist (cm)

41.5 ± 5.4

45.0 ± 5.1

<0.001

Low-density
lipoprotein (mg/dl)

123.2 ± 30.7

121.5 ± 33.6

0.61

High-density
lipoprotein (mg/dl)

61.2 ± 13.7

46.8 ± 11.0

<0.001

Triglycerides (mg/dl)

104.3 ± 48.0

184.6 ± 123.0

<0.001

Systolic blood
pressure (mm Hg)

123.1 ± 14.6

137.3 ± 14.5

<0.001

Diastolic blood
pressure (mm Hg)

68.7 ± 9.8

74.2 ± 10.0

<0.001

Glucose (mg/dl)

91.4 ± 9.1

101.2 ± 15.0

<0.001

Insulin (μU/ml)

12.9 ± 8.1

21.3 ± 15.8

<0.001

2.9 ± 2.0

5.5 ± 4.9

<0.001

Insulin resistance

c

Values are mean ± s.d. with the exception of gender and ethnicity, which are
shown as n (%). bOther = Asian–American or Latino. cInsulin resistance was deter
mined using the homeostasis model of insulin resistance (26). Scores range from
0 to 15, with higher scores indicating greater insulin resistance, and are calcu
lated as the product of the fasting plasma insulin level (in microunits per milliliter)
and the fasting plasma glucose level (in millimoles/liter), divided by 22.5.
a

SF-36. These were, physical functioning (P = 0.021) and general health (P = 0.007). Participants with MetSyn also scored
significantly lower on the physical component summary (PCS)
score (P = 0.013). No differences were observed between those
with and without MetSyn on any of the four subscales of the
SF-36 that assessed dimensions of mental health or in the men
tal component summary score (Table 2).
psychosocial status and lifestyle habits

The psychosocial characteristics of participants with and
without MetSyn are shown in Table 3. No significant differences were observed between the two groups in Beck
table 2 Baseline sF-36 scores for participants with and
without metabolic syndrome among individuals seeking
weight reductiona
No metabolic
syndrome
(n = 226)

Metabolic
syndrome
(n = 135)

P value

Physical functioning

80.6 ± 18.1

75.9 ± 19.5

0.021

Role physical

82.2 ± 30.7

77.6 ± 34.2

0.19

Bodily pain

72.8 ± 21.8

72.7 ± 20.6

0.99

General health

71.3 ± 16.9

66.3 ± 17.7

0.007

Vitality

49.6 ± 18.4

50.5 ± 18.7

0.68

Social function

85.4 ± 19.0

83.5 ± 20.5

0.38

Role emotional

75.5 ± 36.1

80.0 ± 34.6

0.25

Mental health

74.7 ± 15.3

75.1 ± 14.6

0.80

Physical component
summary

49.1 ± 8.4

46.8 ± 8.4

0.013

Mental component
summary

48.6 ± 9.7

49.9 ± 9.2

0.23

Depression Inventory scores or in the percentage of patients
who reported a history of mental health problems or of alco
hol or tobacco use. There also were no significant differences
between groups in the number of psychosocial stressors
(Table 3).
correlations and regression analyses

Correlation and regression analyses are shown in Tables 4
and 5 for the PCS score of the SF-36. In univariable analyses, lower values on the PCS score were associated with the
presence of MetSyn, higher BMI values and depression scores,
and with higher age. By contrast, there was no association
between the PCS score and years of education, gender, ethnicity, alcohol intake, smoking status, or psychosocial stressors
(Table 4).
A forward step-wise regression analysis was conducted
using the four variables that had the strongest association
with the PCS score derived from univariable analysis. They
table 4 univariable correlation of the physical component
summary (pcs) score of the sF-36 with demographic and
psychosocial variables
Variable
BMI

Correlation
coefficient

P value

−0.27

<0.001

−0.23

<0.001

Metabolic syndrome

−0.15

0.004

Age

−0.15

0.005

Depression score

a

Years of education

0.1

0.07

Ever smoker

−0.08

0.11

Drinks per week

−0.07

0.21

SF-36, Medical Outcomes Study, Short Form-36.
a
Values are mean ± s.d.

Number of stressors

0.03

0.52

Ethnicity

0.04

0.53

table 3 psychosocial characteristics and lifestyle habits of
participants with and without metabolic syndrome among
individuals seeking weight reductiona

Gender

0.02

0.69

SF-36, Medical Outcomes Study, Short Form-36.
a
Beck Depression Inventory.

No metabolic
syndromeb

Metabolic
syndromec

P value

Beck Depression Inventory

7.7 ± 6.8

7.7 ± 7.2

0.96

History of mental health
problems, number (%)

58 (26.0%)

33 (24.8%)

0.80

Psychosocial stressors,
total number
Work, number (%)
Health, number (%)
Intimate relationships,
number (%)
Legal/financial, number (%)

1.6 ± 1.4

1.4 ± 1.3

0.21

Variable
Full model
BMI
Depression scorea
Age
Metabolic syndrome

0.07
0.11
0.15
0.15

<0.001
<0.001
<0.001
0.63

Partial model #1
BMI
Age
Metabolic syndrome

0.07
0.10
0.10

<0.001
0.001
0.52

Partial model #2
BMI
Metabolic syndrome

0.07
0.07

<0.001
0.19

Current smoker, number (%)
Ever smoker, number (%)
Alcoholic drinks per week,
number

116 (51.8%)
57 (25.4%)
49 (21.9%)

65 (48.9%)
32 (24.1%)
20 (15.0%)

0.59
0.77
0.11

53 (23.7%)

25 (18.8%)

0.28

9 (4.0%)

4 (3.0%)

0.77

106 (47.3%)

69 (51.9%)

0.41

2.3 ± 3.9

3.0 ± 4.7

0.11

Values are mean ± s.d. for depression score, number of stressors, and drinks
per week; and n (%) for other variables. bn ranges from 219 to 224. cn ranges
from 131 to 133.
a

table 5 Variance in the physical component summary (pcs)
score accounted for by BMI, depression score, age, and the
metabolic syndrome, as determined by forward step-wise
regression

Beck Depression Inventory.

a

Cumulative R2

P value

were entered into the regression according to the strength of
their association—BMI, depression score, age, and MetSyn. As
shown in Table 5, three variables—BMI, depression score, and
age—explained 15% of the variance in the PCS score. MetSyn
did not contribute significantly to the variance explained
after accounting for these three variables. Secondary analyses
showed that the effect of MetSyn was eliminated by controlling
for BMI alone (Table 5).

In summary, the present study found that excess weight
appeared to explain the decrease in HRQoL observed in par
ticipants with MetSyn. Larger studies of more diverse samples
are needed to confirm this finding.
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dIscussIon

This study found that MetSyn was associated with lower
HRQoL on two of the physical subscales of the SF-36. These
were physical function (i.e., limitations in daily activities due
to physical health) and general health (i.e, self-reported over
all health status). In addition, participants with MetSyn scored
significantly lower on the PCS score than did persons with
out the syndrome. By contrast, no association was observed
between MetSyn and the mental component summary score or
any of the SF-36 subscales related to mental health. There also
was no association between MetSyn and symptoms of depres
sion, alcohol or tobacco use, or psychosocial stressors.
Participants in the present study who had MetSyn had a
significantly higher BMI than those without the syndrome
(37.4 kg/m2 vs. 34.7 kg/m2, respectively). Correlation analy
ses showed that both BMI and MetSyn were associated with
a lower PCS score. Results of multiple regression analysis,
however, showed that MetSyn did not account for a signifi
cant amount of the variance in PCS scores after controlling for
BMI. Thus, the reduced HRQoL in participants with MetSyn
appeared to be related to their greater BMI, rather than to
MetSyn per se. Numerous studies have shown that a higher
BMI is associated with lower HRQoL (19–25).
Two previous studies reported that MetSyn was associated
with reduced HRQoL (7,9). However, neither of these inves
tigations controlled for the effect of BMI. In addition, neither
of these studies used standardized criteria to define MetSyn,
such as the criteria used by the National Cholesterol Education
Panel (4) or World Health Organization (10,11). A third study
found lower SF-36 scores at baseline for all eight domains
among a population of surgically treated obese patients, but
no association of lower quality of life with insulin resistance
(19). The other criteria for MetSyn were not examined.
The present study had several limitations. First, patients with
type 2 diabetes were excluded from both of the clinical trials
used for the analysis. Obese individuals with type 2 diabetes
are likely to meet the criteria for MetSyn and may experience
lower HRQoL than persons with the syndrome who do not have
diabetes. Second, our sample consisted principally of persons
from middle- to upper-middle socioeconomic backgrounds
(mean education of 15.6 years in the present analysis). Higher
socioeconomic status may protect obese individuals from the
potential adverse health and psychosocial consequences of
MetSyn. Third, we failed to observe the expected relationship
between psychosocial stress and MetSyn. This may have been
attributable to our use of a suboptimal measure to detect stress.
Future studies should correct this limitation.
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